Susan Thrane

Susan Thrane

Auto-generated profile, based on publicly available information

Susan Thrane

Centre for Medical Parasitology at the Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Cancer Cell
Verified
Journal Article
Closed access
ASAli salanti
Ali salanti
TCThomas M. Clausen
Thomas M. Clausen
MAMette Ørskov Agerbæk
Mette Ørskov Agerbæk
NNNader Al Nakouzi
Nader Al Nakouzi
MDMadeleine Dahlbäck
Madeleine Dahlbäck
MDMads Daugaard
Mads Daugaard

27 April 2016 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
STSusan Thrane
Susan Thrane
CJChristoph M. Janitzek
Christoph M. Janitzek
SMSungwa Matondo
Sungwa Matondo
MRMafalda Resende
Mafalda Resende
TGTobias Gustavsson
Tobias Gustavsson
ABAdam F. Sander Bertelsen
Adam F. Sander Bertelsen
Virus-like particles (VLPs) represent a significant advance in the development of subunit vaccines, combining high safety and efficacy. Their particulate nature and dense repetitive subunit organization makes them ideal scaffolds for display of vaccine antigens. Traditional approaches for VLP-based antigen display require labor-intensive trial-and-error optimization, and often fail to generate dense antigen display. Here we utilize the split-intein (SpyTag/SpyCatcher) conjugation system to generate stable isopeptide bound antigen-VLP complexes by simply mixing of the antigen and VLP components. Genetic fusion of SpyTag or SpyCatcher to the N-terminus and/or C-terminus of the Acinetobacter phage AP205 capsid protein resulted in formation of stable, nonaggregated VLPs expressing one SpyCatcher, one SpyTag or two SpyTags per capsid protein. Mixing of spy-VLPs with eleven different vaccine antigens fused to SpyCatcher or SpyTag resulted in formation of antigen-VLP complexes with coupling efficiencies (% occupancy of total VLP binding sites) ranging from 22–88 %. In mice, spy-VLP vaccines presenting the malaria proteins Pfs25 or VAR2CSA markedly increased antibody titer, affinity, longevity and functional efficacy compared to corresponding vaccines employing monomeric proteins. The spy-VLP vaccines also effectively broke B cell self-tolerance and induced potent and durable antibody responses upon vaccination with cancer or allergy-associated self-antigens (PD-L1, CTLA-4 and IL-5). The spy-VLP system constitutes a versatile and rapid method to develop highly immunogenic VLP-based vaccines. Our data provide proof-of-concept for the technology’s ability to present complex vaccine antigens to the immune system and elicit robust functional antibody responses as well as to efficiently break B cell self-tolerance. The spy-VLP-system may serve as a generic tool for the cost-effective development of effective VLP-vaccines against both infectious- and non-communicable diseases and could facilitate rapid and unbiased screening of vaccine candidate antigens.

12 December 2017 in OncoImmunology
Verified
Journal Article
Open access
Arianna PalladiniArianna Palladini
Arianna Palladini
STSusan Thrane
Susan Thrane
CJChristoph M. Janitzek
Christoph M. Janitzek
JPJessica Pihl
Jessica Pihl
SCStine B. Clemmensen
Stine B. Clemmensen
ABAdam F. Sander Bertelsen
Adam F. Sander Bertelsen
Overexpression of human epidermal growth factor receptor-2 (HER2) occurs in 20–30% of invasive breast cancers. Monoclonal antibody therapy is effective in treating HER2-driven mammary carcinomas, but its utility is limited by high costs, side effects and development of resistance. Active vaccination may represent a safer, more effective and cheaper alternative, although the induction of strong and durable autoantibody responses is hampered by immune-tolerogenic mechanisms. Using a novel virus-like particle (VLP) based vaccine platform we show that directional, high-density display of human HER2 on the surface of VLPs, allows induction of therapeutically potent anti-HER2 autoantibody responses. Prophylactic vaccination reduced spontaneous development of mammary carcinomas by 50%-100% in human HER2 transgenic mice and inhibited the growth of HER2-positive tumors implanted in wild-type mice. The HER2-VLP vaccine shows promise as a new cost-effective modality for prevention and treatment of HER2-positive cancer. The VLP platform may represent an effective tool for development of vaccines against other non-communicable diseases.

23 April 2013 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
STSusan Thrane
Susan Thrane
ALAnne E. Lykkesfeldt
Anne E. Lykkesfeldt
MLMathilde S. Larsen
Mathilde S. Larsen
BSBoe Sorensen
Boe Sorensen
CYChristina W. Yde
Christina W. Yde


5 June 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SSSusheel K. Singh
Susheel K. Singh
STSusan Thrane
Susan Thrane
BCBishwanath K. Chourasia
Bishwanath K. Chourasia
KTKarina Teelen
Karina Teelen
WGWouter Graumans
Wouter Graumans
MTMichael Theisen
Michael Theisen
The Plasmodium falciparum Pfs230 and Pfs48/45 proteins are expressed during transmission from man to mosquito and are leading candidates for a malaria transmission blocking vaccine. Individually they generate transmission blocking (TB) antibodies in rodent models. Whether the single protein vaccines are suitable to use in field settings will primarily depend on their potency to elicit functional antibodies. We hypothesized that a combination of both proteins will be more potent than each protein individually. Therefore we designed chimeric proteins composed of fragments of both Pfs230 and Pfs48/45 as well as single protein fragments, and expressed these in Lactoccus lactis. Both the individual Pfs230 and Pfs48/45 fragments and chimeras elicited high levels of functional antibodies in mice. Importantly, one of the chimeric proteins elicited over threefold higher transmission blocking antibody responses than the single antigens alone. Furthermore the immunogenicity of one of the chimeras could be enhanced through coupling to a virus-like particle (VLP). Altogether these data support further clinical development of these novel constructs.